ArticleVirology journal2016
S1 domain of the porcine epidemic diarrhea virus spike protein as a vaccine antigen.
Article in Virology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 106 citations in OpenAlex.
- Establishment of a blocking ELISA for assessing neutralizing antibody levels against porcine epidemic diarrhea virus.Veterinary research communications · 2026Article
- Efficient design and production of glycosylated PEDV spike S1 protein.Scientific reports · 2026Article
- Development and Efficacy Evaluation of an Indirect ELISA Method Based on the Immunodominant Region of the Spike Protein of Porcine Epidemic Diarrhea Virus.Veterinary sciences · 2026Article
- A Systematic Review and Meta-Analysis of Porcine Epidemic Diarrhea Virus Vaccine Efficacy and Its Modifiers.Animals : an open access journal from MDPI · 2025Review
- Farm animal coronaviruses: the solution is in vaccines.The veterinary quarterly · 2025Review
- Production of Recombinant S1 Protein of Porcine Epidemic Diarrhea Virus in Recombinant CHO Cells for Application in Indirect ELISA.Journal of microbiology and biotechnology · 2025Article
- Clade-Specific Recombination and Mutations Define the Emergence of Porcine Epidemic Diarrhea Virus S-INDEL Lineages.Animals : an open access journal from MDPI · 2025Article
- Advances in porcine epidemic diarrhea virus research: genome, epidemiology, vaccines, and detection methods.Discover nano · 2025Review
- Development of an Indirect ELISA Based on the PEDV S Protein and Evaluation of Its Correlation With Neutralizing Antibody and Immune Protection.Transboundary and emerging diseases · 2025Article
- A nanodiamond-formulated plant protein induces robust immunity against porcine epidemic diarrhea virus in piglets.Frontiers in immunology · 2025Article
- Recombinant SADS-CoV as a vector for porcine epidemic diarrhea vaccine development.Frontiers in immunology · 2025Article
- Research progress and strategies for vaccines and targeted drugs against highly virulent porcine epidemic diarrhea virus.Frontiers in microbiology · 2025Review
- Neutralizing VHH Antibodies Targeting the Spike Protein of PEDV.Veterinary sciences · 2024Article
- Surface display of the COE antigen of porcine epidemic diarrhoea virus on Bacillus subtilis spores.Microbial biotechnology · 2024Article
- High-affinity monoclonal antibodies against the porcine epidemic diarrhea virus S1 protein.BMC veterinary research · 2024Article
- A Comprehensive Review of Our Understanding and Challenges of Viral Vaccines against Swine Pathogens.Viruses · 2024Review
- Review
- Review
- Review
- Spike 1 trimer, a nanoparticle vaccine against porcine epidemic diarrhea virus induces protective immunity challenge in piglets.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPorcine epidemic diarrhea virus (PEDV) is a highly contagious virus infecting pigs of all ages with high morbidity and mortality among newborn piglets. Currently, there is no effective vaccine available to protect the pigs from PEDV. The N-terminal subunit of spike protein (S1) is responsible for virus binding to the cellular receptor and contains a number of neutralizing antibody epitopes. Thus, we expressed and produced recombinant S1 protein to protect newborn piglets by immunization of sows.
methodsAffinity tagged PEDV S1 protein was expressed in a secretory form in yeast, insect and mammalian cells to identify the most suitable production system. Purified recombinant protein was analysed by SDS-PAGE, Western blot and deglycosylation assay. A pregnant sow was intramuscularly immunized three times with adjuvanted recombinant protein prior to farrowing. PEDV-specific immune responses in sera and colostrum of the sow and piglets were assayed by ELISA and virus neutralization assays. Piglets were challenged orally with PEDV, and clinical parameters were monitored for 6 days post-challenge. RESULTS AND
conclusionOf three eukaryotic expression systems tested (yeast, insect-cell, and mammalian), expression by HEK-293 T cells gave the highest yield of protein that was N-glycosylated and was the most appropriate candidate for vaccination. Administration of the subunit vaccine in a sow resulted in induction of S1-specific IgG and IgA that were passively transferred to the suckling piglets. Also, high virus neutralization titres were observed in the serum of the vaccinated sow and its piglets. After PEDV challenge, piglets born to the vaccinated sow exhibited less severe signs of disease and significantly lower mortality compared to the piglets of a control sow. However, there were no significant differences in diarrhea, body weight and virus shedding. Thus, vaccination with S1 subunit vaccine failed to provide complete protection to suckling piglets after challenge exposure, and further improvements are needed for the development of a subunit vaccine that fully protects against PEDV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.